<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03761030</url>
  </required_header>
  <id_info>
    <org_study_id>7733</org_study_id>
    <secondary_id>4R33MH110029-03</secondary_id>
    <nct_id>NCT03761030</nct_id>
  </id_info>
  <brief_title>L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults</brief_title>
  <official_title>Targeting Dopaminergic Mechanisms of Slowing to Improve Late Life Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals with Late Life Depression (LLD) often have cognitive problems, particularly&#xD;
      problems with memory, attention, and problem solving, all of which contribute to&#xD;
      antidepressant non-response. Our group and others have shown that decreased thinking speed is&#xD;
      the central cause of functional problems in patients with LLD. Similarly, decreased walking&#xD;
      speed is associated with depression and carries additional risk for falls, hospitalization,&#xD;
      and death. Available evidence suggests that declining functionality in the brain's dopamine&#xD;
      system contributes to age-related cognitive and motor slowing. The central hypothesis of this&#xD;
      study is that by enhancing dopamine functioning in the brain and improving cognitive and&#xD;
      motor slowing, administration of carbidopa/levodopa (L-DOPA) will improve depressive symptoms&#xD;
      in older adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      N=90 adults of which 30 participants will undergo scanning procedures, aged 60 and older with&#xD;
      (1) a DSM 5 depressive disorder, (2) significant depressive symptoms, and (3) decreased&#xD;
      thinking or walking speed will receive 8 weeks of treatment with L-DOPA up to 450mg. We will&#xD;
      test whether L-DOPA increases brain dopamine release using neuroimaging and whether it speeds&#xD;
      up thinking and walking speed. Data collected in the proposed studies may help identify a new&#xD;
      treatment for LLD, which could have large public health ramifications given the prevalence,&#xD;
      frequent treatment resistance, and chronicity characteristic of LLD. This project also will&#xD;
      elucidate the neurobiology of slowing at molecular, structural, and functional levels of&#xD;
      analysis, increasing our understanding of the interplay between these aging-associated&#xD;
      processes and the pathophysiologic changes underlying late life neuropsychiatric disorders.&#xD;
      Exploring patient characteristics that predict response to L-DOPA may provide useful&#xD;
      information to guide differential therapeutics and develop personalized medicine for LLD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression (HRSD)</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Our target is depressive symptomatology as measured by the Hamilton Rating Scale for Depression (HRSD). The HRSD is a 24-item questionnaire used as an indication of depression and a guide to evaluate recovery. Total scores range from 0-74, not including atypical symptoms sub-scale. A score of 16 or above is typically considered to indicate the presence of depressive symptoms. Higher scores indicate greater severity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Dysthymia</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>L-DOPA Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those assigned to L-DOPA will begin taking 37.5mg carbidopa/150 mg levodopa once daily (with placebo twice daily) for one week, then increase to 75mg carbidopa/300mg levodopa (37.5 mg carbidopa/150mg levodopa twice daily and placebo once daily) for one week, and finally increase to 112.5mg carbidopa/450mg levodopa (37.5 mg carbidopa/150mg levodopa three times daily and no placebo) for the final six weeks. Each subject assigned to the L-DOPA arm will be titrated to 450mg L-DOPA unless they cannot tolerate higher doses, in which case subjects will have their dosage reduced to the maximum tolerable dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects assigned to the placebo arm will take placebo oral tablet three times daily throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-DOPA</intervention_name>
    <description>We will be using generic sinemet 25/100 tablets in this study.</description>
    <arm_group_label>L-DOPA Arm</arm_group_label>
    <other_name>carbidopa/levodopa (Sinemet)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>25/100 placebo tablets</description>
    <arm_group_label>Placebo Arm</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 60 years and older&#xD;
&#xD;
          2. DSM 5 non-psychotic Major Depressive Disorder, Dysthymia, or Depression Not Otherwise&#xD;
             Specified&#xD;
&#xD;
          3. Hamilton Rating Scale for Depression (HRSD) &gt; 15&#xD;
&#xD;
          4. Decreased processing speed (defined as performance &gt; 0.5SD below age-adjusted norms on&#xD;
             Digit Symbol Substitution Test or Trail Making Test Part A) OR decreased gait speed&#xD;
             (defined as average walking speed over 15' course &lt; 1m/s)&#xD;
&#xD;
          5. Willing to and capable of providing informed consent and complying with study&#xD;
             procedures&#xD;
&#xD;
          6. Alternative standard treatments for MDD, Dysthymia, or Depression NOS (e.g.,&#xD;
             antidepressant medication or psychotherapy) have been discussed and the individual&#xD;
             agrees to be involved in an experimental treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of substance abuse or dependence (excluding Tobacco Use Disorder) within the&#xD;
             past 12 months.&#xD;
&#xD;
          2. History of or current psychosis, psychotic disorder, mania, or bipolar disorder&#xD;
&#xD;
          3. Diagnosis of probable Alzheimer's Disease, Vascular Dementia, or Parkinson's Disease&#xD;
             (PD)&#xD;
&#xD;
          4. Mini Mental Status Exam (MMSE) &lt; 25&#xD;
&#xD;
          5. HRSD â‰¥ 28; HRSD suicide item &gt; 2 or the presence of significant suicide risk as judged&#xD;
             by clinician or Clinical Global Impressions (CGI)-Severity score of 7 at baseline.&#xD;
&#xD;
          6. Current or recent (within the past 4 weeks) treatment with antidepressants,&#xD;
             antipsychotics, dopaminergic agents, or mood stabilizers.&#xD;
&#xD;
          7. History of allergy, hypersensitivity reaction, or severe intolerance to L-DOPA&#xD;
&#xD;
          8. Acute, severe, or unstable medical or neurological illness&#xD;
&#xD;
          9. Mobility limiting osteoarthritis of any lower extremity joints, symptomatic lumbar&#xD;
             spine disease, mobility limiting history of joint replacement surgery, or history of&#xD;
             spine surgery&#xD;
&#xD;
             FOR SUBJECTS RECEIVING PET/MRI SCANS ONLY:&#xD;
&#xD;
         10. Having contraindication to MRI scanning (such as metal in body) or unable to tolerate&#xD;
             the scanning procedures&#xD;
&#xD;
         11. History of significant radioactivity exposure (nuclear medicine studies or&#xD;
             occupational exposure)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bret R Rutherford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Clinical Psychiatry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marika Chrisanthopoulos</last_name>
    <phone>646-774-8697</phone>
    <email>marika.chrisanthopoulos@nyspi.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bret R Rutherford, MD</last_name>
    <phone>646774-8660</phone>
    <email>brr8@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marika Chrisanthopoulos, MA</last_name>
      <phone>646-772-8697</phone>
      <email>marika.chrisanthopoulos@nyspi.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Bret R Rutherford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Brown, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 29, 2018</study_first_submitted>
  <study_first_submitted_qc>November 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Bret Rutherford</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Depressive symptoms</keyword>
  <keyword>Cognitive problems</keyword>
  <keyword>Antidepressant non-response</keyword>
  <keyword>Dopamine system</keyword>
  <keyword>Older Adults</keyword>
  <keyword>Motor slowing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Dysthymic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

